A Factor IX product will be the target.

BAC entered into a collaboration with Octapharma, a plasma protein company specializing in the development, production, and sale of plasma derivatives and recombinant plasma proteins. The objective of the collaboration is to discover and develop a custom CaptureSelect® ligand for the purification of a recombinant Factor IX product developed by Octapharma for the prophylaxis and treatment of bleeding in Haemophilia B.

Octapharma will use the CaptureSelect ligand in the downstream processing of this protein from mammalian cell lines.

Previous articleOncolys Opts for Asian Rights to Tacere’s HCV Treatment for $60M
Next articleCobra Biomanufacturing Receives French Approval for R&D Tax Credit